1-3 of 3
David G. Coffey
Close
Sort by
Journal Articles

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL

Clinical Trials & Observations
Solomon A. Graf, Ryan C. Lynch, Chaitra S. Ujjani, Ted A. Gooley, Heather Rasmussen, David G. Coffey, Andrew J. Cowan, Stephen D. Smith, Mazyar Shadman, Edus H. Warren, Edward N. Libby, III, Alexander L. Greninger, Jonathan R. Fromm, Ajay K. Gopal
Journal: Blood Advances
Blood Adv (2023) 7 (5): 687–696.
https://doi.org/10.1182/bloodadvances.2022008628
Published: 2023
Includes: Supplemental data
Journal Articles

High-throughput sequencing reveals novel features of immunoglobulin gene rearrangements in Burkitt lymphoma

Katharine A. Lombardo, David G. Coffey, Alicia J. Morales, Christopher S. Carlson, Andrea M. H. Towlerton, Sarah E. Gerdts, Francis K. Nkrumah, Janet Neequaye, Robert J. Biggar, Jackson Orem, Corey Casper, Sam M. Mbulaiteye, Kishor G. Bhatia, Edus H. Warren
Journal: Blood Advances
Blood Adv (2017) 1 (16): 1261–1262.
https://doi.org/10.1182/bloodadvances.2017008060
Published: 2017
Journal Articles

High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis

Global Advances
Katharine A. Lombardo, David G. Coffey, Alicia J. Morales, Christopher S. Carlson, Andrea M. H. Towlerton, Sarah E. Gerdts, Francis K. Nkrumah, Janet Neequaye, Robert J. Biggar, Jackson Orem, Corey Casper, Sam M. Mbulaiteye, Kishor G. Bhatia, Edus H. Warren
Journal: Blood Advances
Blood Adv (2017) 1 (9): 535–544.
https://doi.org/10.1182/bloodadvances.2016000794
Published: 2017
Includes: Supplemental data